Expression of Programmed Death-1 (PD-1) & Programmed Death Ligand-1 (PDL-1) in Acute Lymphoblastic Leukemia in Pediatric
Condition(s):Acute Lymphoblastic Leukemia in PediatricLast Updated:June 22, 2022Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):Acute Lymphoblastic Leukemia in PediatricLast Updated:June 22, 2022Not yet recruiting
Condition(s):Leukemia, AcuteLast Updated:August 1, 2023Completed
Condition(s):Acute Lymphoblastic Leukemia, Pediatric; Adverse Drug EventLast Updated:February 16, 2023Completed
Condition(s):Acute Lymphoblastic Leukemia, AdultLast Updated:January 9, 2024Recruiting
Condition(s):B-Cell Pediatric ALLLast Updated:April 6, 2017Terminated
Condition(s):Precursor Cell Lymphoblastic Leukemia-LymphomaLast Updated:March 3, 2023Recruiting
Condition(s):Pediatric Patients With Acute Lymphoblastic LeukemiaLast Updated:May 3, 2019Completed
Condition(s):Acute Lymphoblastic Leukemia, PediatricLast Updated:February 14, 2024Not yet recruiting
Condition(s):Acute Lymphoblastic LeukemiaLast Updated:May 9, 2018Unknown status
Condition(s):Leukemia, Lymphoblastic, Acute, PediatricLast Updated:May 27, 2022Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.